CLINICAL RESEARCH: ELECTROPHYSIOLOGY: VIEWPOINT
Is defibrillation testing required for defibrillator implantation?
S. Adam Strickberger, MD*,* and
George J. Klein, MD
* Division of Cardiology, Washington Hospital Center, Washington, DC, USA
Division of Cardiology, University of Ontario, London, Ontario, Canada
Manuscript received September 11, 2003;
revised manuscript received November 17, 2003,
accepted November 24, 2003.
* Reprint requests and correspondence: Dr. S. Adam Strickberger, 110 Irving Street, NW #5A-12, Washington, DC 20010-2975, USA.
strickberger{at}medstar.net
The assessment of defibrillation (DFT) efficacy has long been the standard of care during defibrillator implantation. To ensure an acceptable DFT safety margin, early defibrillator systems frequently required that the shock polarity and the location, type, or number of electrodes had to be altered. Advances in defibrillator and lead technology have resulted in lower and more consistent DFT thresholds in the range of 10 J, with an infrequent requirement to modify the DFT system. Yet, one can make an argument for and against continuation of DFT testing at the time of defibrillator implantation. The goal of this paper is to address both the data that do support and the data that do not support continuation of DFT testing at the time of device implantation. Scientifically, DFT testing should be abandoned only when prospective evidence demonstrates that defibrillator implantation without testing is as safe and has the same mortality benefits as implantation with testing. The most attractive aspect of eliminating DFT efficacy testing is that more patients may have the opportunity to be treated with this life-saving therapy. Perhaps there are alternative strategies to improve accessibility to defibrillator therapy without possibly eroding its effectiveness. In the end, will lives be saved or lost if we discontinue DFT efficacy testing and lower the barriers to implantable defibrillator therapy?
|
Abbreviations and Acronyms
| | DFT | = defibrillation | | VF | = ventricular fibrillation |
|
This article has been cited by other articles:
|
|
|
|
 
A. B. Curtis
Defibrillation Threshold Testing in Implantable Cardioverter-Defibrillators: Might Less Be More Than Enough?
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
557 - 558.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Day, B. Olshansky, S. Moore, S. Brown, K. Q. Stolen, D. R. Lerew, and for the INTRINSIC RV Study Investigators
High defibrillation energy requirements are encountered rarely with modern dual-chamber implantable cardioverter-defibrillator systems
Europace,
March 1, 2008;
10(3):
347 - 350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Brignole, G. Raciti, M. G. Bongiorni, G. De Martino, S. Favale, M. Gasparini, R. Luise, E. Occhetta, and A. Proclemer
Defibrillation testing at the time of implantation of cardioverter defibrillator in the clinical practice: a nation-wide survey
Europace,
July 1, 2007;
9(7):
540 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Day, R. N. Doshi, P. Belott, U. Birgersdotter-Green, M. Behboodikhah, P. Ott, K. A. Glatter, S. Tobias, H. Frumin, B. K. Lee, et al.
Inductionless or Limited Shock Testing Is Possible in Most Patients With Implantable Cardioverter- Defibrillators/Cardiac Resynchronization Therapy Defibrillators: Results of the Multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations)
Circulation,
May 8, 2007;
115(18):
2382 - 2389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. K. Kantharia
Defibrillation thresholds testing of implantable cardioverter-defibrillators at implantation
J. Am. Coll. Cardiol.,
February 1, 2005;
45(3):
468 - 468.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A.M.J. Theuns, T. Szili-Torok, and L. J. Jordaens
Defibrillation efficacy testing: Long-term follow-up and mortality
Europace,
January 1, 2005;
7(6):
509 - 515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
